Tivicay, Tivicay Pd (dolutegravir) is a small molecule pharmaceutical. Dolutegravir was first approved as Tivicay on 2013-08-12. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. Tivicay's patent is valid until 2029-12-08 (FDA).
|Drug Class||Antivirals: integrase inhibitors|